GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a long and complex history. Its stock price reflects past failures in clinical trials, particularly in oncology. Its current performance reflects its attempts to restructure R&D and restore investor confidence.
Share prices of companies in the market segment - Pharma immune
Nektar is a biotech company with a long and complex history. Its segments are based on its polymer technology, which enhances the properties of drugs. We classify it as part of the Pharma-immune sector, and the chart below reflects the dynamics of the entire industry, as well as Nektar's own history of clinical failures.
Broad Market Index - GURU.Markets
Nektar Therapeutics is a biopharmaceutical company developing drugs for the treatment of oncology and autoimmune diseases using its polymer technology. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Nektar shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
NKTR - Daily change in the company's share price Nektar Therapeutics
Nektar Therapeutics' daily price change is a measure of its sensitivity to clinical trial results. Change_co reflects the high volatility inherent in the biotech sector, where development failures lead to sharp declines. This metric is important for analyzing risky biotech companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma immune
Nektar Therapeutics is a biotech company. This chart highlights the extreme volatility of the sector. Comparing it to NKTR, which is undergoing a complex restructuring, helps assess its risks compared to more stable players.
Daily change in the price of a broad market stock, index - GURU.Markets
Nektar is a biopharmaceutical company whose cancer drug story exemplifies the extreme volatility of biotech. The chart below illustrates general market fluctuations, making Nektar's drama particularly instructive.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Nektar Therapeutics
Nektar is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Nektar Therapeutics is a biopharmaceutical company developing drugs in oncology and immunology. Following clinical trial failures, it is undergoing a restructuring. The chart below shows how the market views its new strategy and the potential of its scientific platform.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nektar is the story of a biotech star's fall after the failure of a key drug. Its stock price reflects not economic cycles, but its desperate attempts to find a new path and regain investor confidence. The chart is a visual aid for how a single scientific failure can wipe out years of value.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Nektar Therapeutics
Nektar, a biopharmaceutical company with a long history of ups and downs, has a monthly price fluctuations that reflect the results of clinical trials of its drug candidates in immuno-oncology and autoimmune diseases, making it highly volatile.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Immunology is a promising but unpredictable field of biotechnology, where clinical failures can devastate stock prices. The sector's performance, shown in the chart, reflects these risks. This is the backdrop against which a company like Nektar Therapeutics is attempting to rehabilitate its scientific potential after past setbacks.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nektar Therapeutics, a biopharmaceutical company focused on immunology, has a volatile history. Its shares react sharply to clinical trial results, particularly in oncology. Their performance is unpredictable and independent of overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Nektar Therapeutics
Shares of Nektar Therapeutics, a biotech company with a long history of ups and downs, exhibit high volatility on a weekly basis. Short-term price movements depend on news about clinical trials of its immunology drugs and partnerships with major pharma.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Nektar Therapeutics shares, like the entire biotech sector, are highly dependent on overall investor risk sentiment. Regulatory news and scientific breakthroughs in immunology can boost the entire industry. The chart allows you to compare how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Nektar Therapeutics, like many biotech companies, can exhibit dynamics completely unrelated to the market. Positive clinical trial data can cause its shares to skyrocket even on the day the S&P 500 is plunging. The chart will show these moments of "living in its own world."
Market capitalization of the company, segment and market as a whole
NKTR - Market capitalization of the company Nektar Therapeutics
Nektar Therapeutics' market capitalization chart is a financial history of the ups and downs of the biotech world. It reflects both the early hopes for its platform to improve existing drugs and the subsequent disappointments of clinical failures. Its current dynamics are investors' attempt to estimate the remaining value of the company's technologies and development pipeline.
NKTR - Share of the company's market capitalization Nektar Therapeutics within the market segment - Pharma immune
Nektar Therapeutics is a biopharmaceutical company developing drugs based on its polymeric chemical platform, which enhances drug performance. Its market share reflects the potential of this technology. The chart shows how the market values its diverse development portfolio in oncology and immunology.
Market capitalization of the market segment - Pharma immune
Nektar Therapeutics develops drugs based on its polymer chemistry platform. The chart below shows the overall market capitalization of the immunopharmaceuticals sector. It reflects the ups and downs of biotech development. Against this backdrop, Nektar's story is one of great hopes and painful setbacks.
Market capitalization of all companies included in a broad market index - GURU.Markets
The development of new drugs, as seen on the chart, is full of ups and downs. Nektar Therapeutics specializes in modifying molecules to improve their therapeutic properties. Its market capitalization reflects both past failures in oncology and hopes for success for its platform in other fields, such as immunology.
Book value capitalization of the company, segment and market as a whole
NKTR - Book value capitalization of the company Nektar Therapeutics
Nektar's book value is the material basis for developing innovative drugs. The chart reflects the value of its production facilities and laboratories, where drugs are created using unique polymer chemistry technology. These are physical assets aimed at improving therapeutics in oncology and immunology.
NKTR - Share of the company's book capitalization Nektar Therapeutics within the market segment - Pharma immune
Nektar Therapeutics, a biopharmaceutical company, has significant R&D and manufacturing capabilities. Its stake in the sector reflects its ownership of laboratories and equipment for developing its unique polymer conjugates, which enhance drug performance.
Market segment balance sheet capitalization - Pharma immune
Nektar Therapeutics develops innovative drugs. Pharmaceuticals, as the chart shows, are capital-intensive. Nektar uses a platform approach; its capital comes not so much from factories as from patented technologies for improving drug properties.
Book value of all companies included in the broad market index - GURU.Markets
Nektar Therapeutics develops innovative drugs based on its polymeric chemical platform. Its book value reflects investments in this platform, manufacturing capacity, and numerous clinical programs in oncology and immunology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Nektar Therapeutics
Nektar Therapeutics is a biotech company. Its valuation has fallen below book value following the failure of a key clinical trial. The chart shows how the market is losing faith in the company's scientific platform and is valuing it primarily on its cash balance.
Market to book capitalization ratio in a market segment - Pharma immune
Nektar Therapeutics is a biopharmaceutical company developing drugs in oncology and immunology. Its valuation is dependent on clinical trial results. This chart shows how investor expectations for its scientific platforms and future drugs compare with its current tangible assets.
Market to book capitalization ratio for the market as a whole
Nektar Therapeutics is a biotech company whose hopes were pinned on a cancer drug that failed key trials. Compared to the average market valuations shown in the chart, its current low valuation reflects investor disappointment and uncertainty about the future of its scientific platform.
Debts of the company, segment and market as a whole
NKTR - Company debts Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company developing new drugs in oncology and immunology. Long-term and expensive clinical trials require significant funding. This chart illustrates how the company uses various financial instruments, including debt, to support its numerous research programs and partnerships.
Market segment debts - Pharma immune
Nektar Therapeutics is a biotech company that suffered significant setbacks in clinical trials, which severely impacted its financial position. In this situation, managing its remaining cash and any debt obligations becomes critical to survival. This chart shows the company's current balance sheet.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Nektar Therapeutics
Nektar Therapeutics develops immuno-oncology drugs. This chart shows the financial structure of the company, which has experienced both successes and setbacks in research. Debt in this context is a risk indicator. The ability to service debt directly depends on progress in clinical trials and partnerships with major pharmaceutical companies.
Market segment debt to market segment book capitalization - Pharma immune
Nektar Therapeutics is a biopharmaceutical company developing new drugs in oncology and immunology. R&D in this field is very expensive. This chart reflects the industry's collective debt load, allowing investors to assess how aggressively or conservatively Nektar uses debt to finance its long-term projects.
Debt to book value of all companies in the market
Nektar Therapeutics develops drugs in oncology and immunology. A long and expensive R&D cycle requires stable funding. This chart shows general conditions in the credit markets, allowing investors to assess Nektar's financial flexibility: whether the company has access to debt financing or is entirely dependent on the success of its drugs and shareholder confidence.
P/E of the company, segment and market as a whole
P/E - Nektar Therapeutics
This chart for Nektar Therapeutics illustrates the rollercoaster ride of biotech. The company's P/E is often negative or abnormal, reflecting a history of clinical trial failures. The valuation reflects market skepticism and the belief of only the most optimistic investors that its scientific platform will ultimately yield results.
P/E of the market segment - Pharma immune
Nektar Therapeutics is a biopharmaceutical company specializing in drug development based on its polymeric chemical platform, which enhances drug properties. This chart shows the average valuation for the biotech sector, helping to understand how investors view Nektar's scientific platform and clinical pipeline after a series of setbacks.
P/E of the market as a whole
Nektar Therapeutics is a biotech company developing drugs in oncology and immunology. Its valuation reflects investor confidence in its scientific platform after a series of past setbacks. The overall market sentiment shown in this chart serves only as a backdrop, while Nektar's key objective is to generate positive research data to regain investor confidence.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company developing drugs to treat cancer, autoimmune diseases, and other conditions. Its value depends on the results of lengthy and expensive clinical trials. This chart shows the market's assessment of the likelihood of success for its key developments, reflecting the company's expected future revenue from new drugs in its current price.
%20P%2FE%20Nektar%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Nektar-Therapeutics&v=1772635847293 "Chart of the company's future (projected) P/E Nektar Therapeutics")
Future (projected) P/E of the market segment - Pharma immune
Nektar Therapeutics is a biopharmaceutical company developing drugs in oncology and immunology using its polymer chemistry technology. This chart shows general profitability expectations for the biotech sector. NKTR's position relative to the average reflects the market's opinion of the potential of their scientific platform after a series of past clinical failures.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772635847324 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Nektar Therapeutics develops innovative drugs, for example, in the field of immuno-oncology. Valuing such companies is a bet on future scientific success. This chart shows the market's overall risk tolerance. During periods of optimism, investors are more favorable to biotech companies with long development cycles and high potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772635847363 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company developing new drugs in oncology and immunology. This chart shows the company's financial performance, which is heavily dependent on clinical trial results and partnerships with major pharmaceutical companies to commercialize its developments.
Profit of companies in the market segment - Pharma immune
Nektar Therapeutics develops innovative drugs in areas such as oncology and autoimmune diseases using its polymer chemistry technology. The company's future depends on the approval of its drugs. This chart shows the overall profitability of the immunopharmaceutical industry. It is an indicator of the industry's success in developing and bringing new generations of drugs to market.
Overall market profit
Nektar Therapeutics creates innovative drugs by modifying the chemical structure of existing molecules. Its success depends on the results of clinical trials and partnerships with major pharmaceutical companies. The overall economic situation, reflected in the graph, influences the willingness of industry giants to invest in new developments and enter into licensing agreements, which is important for Nektar.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Nektar Therapeutics
Nektar Therapeutics develops innovative drugs in oncology and immunology. The company's future profitability depends on the clinical trial results of its key drug candidates. This chart shows analysts' expectations for the scientific and commercial potential of Nektar's pipeline, which is associated with high risks in biotech development.
%20profit%20of%20the%20company%20Nektar%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Nektar-Therapeutics&v=1772635847473 "Graph of future (projected) profit of the company Nektar Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Nektar Therapeutics is a biotech company developing drugs for the treatment of oncology and autoimmune diseases. Its value and prospects are directly dependent on the results of clinical trials and partnerships with major pharmaceutical companies. This chart shows forecasts for the entire biotech sector, helping to assess Nektar's potential and risks relative to the broader industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772635847489 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Nektar Therapeutics develops drugs in oncology and immunology. The company's financial results depend on the success of clinical trials, partnerships with major pharmaceutical companies, and regulatory approvals. This chart, which shows general economic trends, has minimal impact on its core business.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772635847517 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company developing drugs in oncology and immunology. This chart reflects the turbulent history of its clinical development. Sharp ups and downs in this indicator directly correlate with news of the successes or failures of key clinical trials, highlighting the high risk nature of biotech investments.
P/S market segment - Pharma immune
Nektar Therapeutics develops innovative drugs in oncology and immunology using its polymeric chemistry platform. The company's revenue depends on partnerships and the future success of its drugs. This biotech chart helps assess how the market values Nektar's technology platform and its potential for creating new therapeutic molecules.
P/S of the market as a whole
Nektar Therapeutics is a biopharmaceutical company developing drugs in oncology, immunology, and virology. Its platform enables the improvement of existing drugs. The company's valuation is highly dependent on clinical trial results. This chart shows how the market as a whole values revenue, providing context for understanding Nektar's volatile valuation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company using its polymer chemistry technology to improve existing drugs. Its future depends on the success of clinical trials and partnerships. This chart shows how investors assess the potential for future revenue from licensing fees and sales of drugs based on its platform.
%20P%2FS%20Nektar%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Nektar-Therapeutics&v=1772635847721 "The graph of the company's future (projected) P/S Nektar Therapeutics")
Future (projected) P/S of the market segment - Pharma immune
Nektar Therapeutics is a biopharmaceutical company using its polymer chemistry platform to develop new drugs, including in immuno-oncology and autoimmune diseases. The company's valuation reflects investors' opinions on the potential of its scientific platform after a series of high-profile clinical trial failures, making it a risky bet on science.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772635847752 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Nektar Therapeutics is a biotechnology company developing drugs in oncology and immunology. Its prospects depend on the success of its clinical programs. In the context of the overall revenue forecasts shown in the chart, Nektar is betting on scientific innovation.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772635847838 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that uses its polymer chemistry technology to improve existing drugs. Its revenue, shown in this chart, comes not from direct sales but from royalties, license fees, and milestone payments from major pharmaceutical partners, such as Bristol-Myers Squibb.
Sales of companies in the market segment - Pharma immune
Nektar Therapeutics (NKTR) is a biopharmaceutical company developing drugs for the treatment of cancer, autoimmune diseases, and chronic diseases. Its core technology enables improvements in the properties of existing drugs. This metric reflects overall revenue in the immunology sector, where Nektar's innovative platforms can create new standards of therapy.
Overall market sales
Nektar Therapeutics develops innovative drugs in oncology and immunology. For a company in the research stage, an influx of investment capital is important. This graph, reflecting the overall health of the economy, influences investors' risk appetite. During periods of growth, they are more willing to fund promising but long-term biotech projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Nektar Therapeutics
Nektar Therapeutics is a biotechnology company developing drugs for the treatment of cancer, autoimmune diseases, and chronic diseases. Its revenue depends on the success of clinical trials, partnerships, and royalties. This chart reflects analyst expectations, which assess the scientific potential and commercial prospects of its developments in complex medical areas.
%20sales%20of%20the%20company%20Nektar%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Nektar-Therapeutics&v=1772635848221 "Schedule of future (projected) sales of the company Nektar Therapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Nektar Therapeutics is a biopharmaceutical company developing drugs based on its polymer chemistry technology. This forecast chart reflects potential future revenue from royalties and partnerships for their developments. It shows which of their scientific programs and partnerships analysts consider the most promising.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772635848347 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Nektar Therapeutics is a biopharmaceutical company developing drugs based on its polymer chemistry technology, primarily in oncology and immunology. Its valuation depends on its R&D success. This graph, reflecting investor sentiment, influences the availability of capital to fund expensive and time-consuming clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772635848423 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company specializing in the development of new drugs for the treatment of cancer, autoimmune diseases, and chronic diseases. Its profitability depends on the success of clinical trials and partnerships with major pharmaceutical companies. The chart reflects the company's financial performance during the expensive research phase, which determines future commercial success.
Market segment marginality - Pharma immune
Nektar Therapeutics is a biopharmaceutical company developing drugs in oncology and immunology using its polymeric chemical platform. This chart reflects its operating expenses. Profitability will only be positive if the drugs in development are successfully commercialized or if major partnerships are concluded.
Market marginality as a whole
Nektar Therapeutics is a biopharmaceutical company developing drugs in oncology and immunology. Its shares and market cap are sensitive to research results and overall sentiment in the sector. This total return chart serves as a backdrop. It shows how much risk investors are willing to take on long, expensive developments with uncertain outcomes.
Employees in the company, segment and market as a whole
Number of employees in the company Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company developing new drugs in oncology and immunology. Its headcount dynamics are closely tied to clinical trial results. Staff growth typically accompanies successful trials and preparation for commercialization, while failures can lead to layoffs.
Share of the company's employees Nektar Therapeutics within the market segment - Pharma immune
Nektar Therapeutics is a biopharmaceutical company developing new drugs for the treatment of cancer, autoimmune diseases, and chronic diseases. Its core assets are its scientific platform and research team. This chart demonstrates the scale of its investment in human capital, reflecting the size of the team working on the development of next-generation drug candidates.
Number of employees in the market segment - Pharma immune
Nektar Therapeutics develops drugs in oncology and immunology. The presented employment chart in the immunopharmacology sector illustrates the intensity of the race to develop new cancer treatments. For Nektar, the growing number of specialists means both enormous scientific potential for partnerships and intense competition for breakthrough clinical results.
Number of employees in the market as a whole
Nektar Therapeutics is a biopharmaceutical company specializing in immunology. Like other clinical-stage biotechs, its need for scientists and researchers is determined by progress in drug development. This schedule provides the macroeconomic backdrop against which the company must secure funding and attract talent.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Nektar Therapeutics (NKTR)
Nektar Therapeutics is a biopharmaceutical company specializing in the development of drugs for the treatment of cancer and autoimmune diseases. Its business is driven by scientific research. This chart illustrates how highly the market values the potential of its scientific platform and development pipeline, enabling a small team of scientists to create enormous shareholder value.
%20of%20the%20company%20Nektar%20Therapeutics%20(NKTR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Nektar-Therapeutics-NKTR&v=1772635848689 "Chart of market capitalization per employee (in thousands of dollars) of the company Nektar Therapeutics (NKTR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Nektar Therapeutics specializes in drug development in immuno-oncology and autoimmune diseases. The company's value is determined by its scientific platform and development pipeline. This metric reflects the premium the market places on innovative potential per scientist capable of creating a breakthrough drug.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772635848720 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Nektar Therapeutics is a biopharmaceutical company specializing in the development of drugs for cancer and autoimmune diseases. The chart reflects the market valuation of its scientific platform and development pipeline. The high cost per employee demonstrates that the company's value lies in its intellectual property and decades of research, not in its manufacturing assets.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772635848777 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Nektar Therapeutics (NKTR)
Nektar Therapeutics is a biotech company developing drugs in oncology and immunology. Following clinical trial failures, the company is undergoing restructuring. This chart illustrates how difficult it is for the company to generate profits (or how large the losses are) based on its remaining staff while it seeks new growth opportunities.
%20Chart%20Nektar%20Therapeutics%20(NKTR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Nektar-Therapeutics-NKTR&v=1772635848909 "Company Profit Per Employee (in thousands of dollars) Chart Nektar Therapeutics (NKTR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Nektar Therapeutics is a biopharma... (clarification: the company experienced major R&D setbacks). Nektar's business is focused on developing immuno-oncology drugs. After the failure of a key study, the company drastically reduced its staff. This chart reflects a difficult period when the company is trying to reduce capital burn per employee while seeking a new path.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772635848952 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Nektar Therapeutics is a biotech company developing drugs, including in the field of immuno-oncology. The company uses its proprietary platform to improve the performance of existing drugs. This indicator demonstrates that even at the development or early commercialization stage, profitability per employee in biotech can fluctuate significantly depending on the success of clinical trials or partnerships.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772635848997 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Nektar Therapeutics (NKTR)
Nektar Therapeutics is a biopharmaceutical company developing drugs to treat cancer and autoimmune diseases. Its revenue per employee comes primarily from royalties and partnership fees, rather than direct sales. The chart reflects this revenue from partnerships with major pharmaceutical companies that use its technology platform.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Nektar-Therapeutics-NKTR&v=1772635849135 "Sales chart per company employee Nektar Therapeutics (NKTR)")
Sales per employee in the market segment - Pharma immune
Nektar Therapeutics (NKTR) is a biotech company using its polymer chemistry platform to develop drugs, primarily in the field of immuno-oncology. This chart shows the average revenue per employee in this segment. It helps assess how effectively NKTR generates revenue (from partnerships or sales) through its scientific team.
Sales per employee for the market as a whole
Nektar Therapeutics (NKTR) is a biotechnology company using its platform technology to develop new drugs, including in immuno-oncology. The company has both in-house developments and partner programs. This metric reflects how successfully the company generates revenue (in the form of royalties, license fees, or, in the past, sales) relative to its large scientific and administrative staff.
Short shares by company, segment and market as a whole
Shares shorted by company Nektar Therapeutics (NKTR)
Nektar Therapeutics (NKTR) is a long-established biotech company specializing in modifying existing drugs to improve their profile. The company has experienced several major failures in clinical trials. This chart shows the level of mistrust. The high number of short positions reflects the legacy of past failures and investor doubts about the value of drugs remaining in development. (345)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Nektar-Therapeutics-NKTR&v=1772635849216 "Short Shares Chart for the Company Nektar Therapeutics (NKTR)")
Shares shorted by market segment - Pharma immune
Nektar Therapeutics is a biotech company known for its "pegylation" (drug enhancement) platform and high-profile failures in oncology. This chart reflects the overall sentiment in the sector. It reflects the extreme pessimism of investors toward biotech companies whose key R&D projects have failed.
Shares shorted by the overall market
Nektar Therapeutics is a biotech company that has suffered several clinical trial failures. Its reputation among investors is already unstable. When this chart shows rising general fear, investors are the first to sell off "problematic" and speculative stories. Trust in companies like NKTR plummets during periods of panic.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Nektar Therapeutics (NKTR)
Nektar Therapeutics (NKTR) is a biotech company specializing in drug development (primarily in oncology) using its polymer conjugation technology to enhance their properties. This chart measures sentiment. It often shows "oversold" (below 30) after high-profile clinical trial failures or "overbought" (above 70) on hopes for new developments.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Nektar-Therapeutics-NKTR&v=1772635849315 "RSI 14 indicator chart for the company's stock Nektar Therapeutics (NKTR)")
RSI 14 Market Segment - Pharma immune
Nektar Therapeutics (NKTR) is a biotech company developing polymer-based drugs for the treatment of cancer and autoimmune diseases. Their path has been highly volatile. This chart tracks overall sentiment in the Pharma/Immunology sector. It helps investors understand whether NKTR's performance reflects their challenging trials or whether the entire sector is overheated or oversold.
RSI 14 for the overall market
Nektar Therapeutics (NKTR) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NKTR (Nektar Therapeutics)
Nektar Therapeutics is a biopharmaceutical company undergoing transformation following setbacks in oncology drug development. Its value now depends on its remaining assets and partnerships. This chart shows the average target price analysts are predicting for the company's future prospects.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NKTR-Nektar-Therapeutics&v=1772635849454 "A chart showing analyst consensus forecasts for the expected stock price. NKTR (Nektar Therapeutics)")
The difference between the consensus estimate and the actual stock price NKTR (Nektar Therapeutics)
Nektar Therapeutics is a biotech company whose core technology, PEGylation, was supposed to improve existing drugs. Following the failure of their key oncology drug, the company is in crisis. This chart reflects analysts' skepticism and their attempts to estimate the value of the company's remaining technologies.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NKTR-Nektar-Therapeutics&v=1772635849494 "A chart showing the difference between the consensus forecast and the actual stock price. NKTR (Nektar Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Nektar Therapeutics is a biotech company whose polymerization platform enables the improvement of existing drugs. Following a failure in oncology, the company is exploring new applications. This chart shows analysts' overall expectations for the entire immunopharmaceutical sector. It reflects whether experts believe the company can find new applications for its technology.
Analysts' consensus forecast for the overall market share price
Nektar Therapeutics is a biotech company specializing in drug development (for example, in oncology) using its proprietary PEGylation technology, which improves drug performance. This chart shows overall risk appetite. For Nektar, whose success depends on clinical trial results, overall market optimism is important for funding and supporting its valuation.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Nektar Therapeutics
Nektar Therapeutics is a biotech company with a platform designed to improve existing drugs. They survived the catastrophic failure of their flagship oncology drug, which devastated their valuation. This chart is an assessment of their second chance. It reflects their efforts to restructure their R&D pipeline, focusing on new immunology candidates, and restore investor confidence.
AKIMA Market Segment Index - Pharma immune
Nektar (NKTR) is a veteran biotech (R&D-focused) that (following the failure of a key oncology drug) is undergoing a restructuring, focusing on new immunology programs. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this risky R&D model (NKTR) differentiate it from the average pharma company?
The AKIM Index for the overall market
Nektar Therapeutics is a biotech company, a pioneer in polymer chemistry, developing drugs for the immune system (immunology, oncology). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this company, which is undergoing pipeline restructuring, compares to overall economic trends.
